Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.
Carter M SuryadevaraRupen DesaiS Harrison FarberBryan D ChoiAdam M SwartzSteven H ShenPatrick C GedeonDavid J SnyderJames E HerndonPatrick HealyElizabeth A ReapGary E ArcherPeter E FecciJohn H SampsonLuis Sanchez-PerezPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
In the absence of lymphodepletion, CARs targeting solid tumors are hindered by Treg immunosuppression and poor persistence. Here, CARs were modified to circumvent Treg suppression and to simultaneously improve in vivo engraftment. Modified CARs treated solid tumors without a need for lymphodepletion.